Autolus Therapeutics (NASDAQ:AUTL) Stock Picked Up by Analysts at HC Wainwright

Equities researchers at HC Wainwright began coverage on shares of Autolus Therapeutics (NASDAQ:AUTL) in a research note issued to investors on Monday, Benzinga reports. The firm set a “buy” rating on the stock.

AUTL has been the subject of several other reports. Weiss Ratings upgraded Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Wall Street Zen upgraded shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Autolus Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Autolus Therapeutics Price Performance

Shares of Autolus Therapeutics stock opened at $1.52 on Monday. The company has a 50-day simple moving average of $1.91 and a two-hundred day simple moving average of $1.67. The stock has a market capitalization of $404.57 million, a PE ratio of -1.43 and a beta of 2.15. Autolus Therapeutics has a 52-week low of $1.18 and a 52-week high of $2.58. The company has a debt-to-equity ratio of 1.04, a quick ratio of 4.40 and a current ratio of 4.89.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.06. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. The company had revenue of $45.69 million during the quarter, compared to the consensus estimate of $38.56 million. On average, analysts anticipate that Autolus Therapeutics will post -0.76 EPS for the current fiscal year.

Institutional Trading of Autolus Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Syncona Portfolio Ltd bought a new stake in Autolus Therapeutics during the 2nd quarter worth approximately $26,625,152. Alphabet Inc. bought a new position in shares of Autolus Therapeutics in the second quarter worth approximately $1,117,000. Cetera Investment Advisers boosted its position in shares of Autolus Therapeutics by 2.7% in the first quarter. Cetera Investment Advisers now owns 1,129,074 shares of the company’s stock worth $1,558,000 after purchasing an additional 29,324 shares during the period. Waverly Advisors LLC bought a new position in shares of Autolus Therapeutics in the first quarter worth approximately $37,000. Finally, Vise Technologies Inc. purchased a new stake in shares of Autolus Therapeutics in the third quarter worth $35,000. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing programmed T-cell therapies for cancer. The company’s approach is designed to engineer T cells to recognize and eliminate malignant cells while incorporating features intended to improve activity, persistence and safety.

Its lead product, obecabtagene autoleucel, is an autologous CAR T-cell therapy marketed in the United States under the brand name Aucatzyl. It is used to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.